The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected ...

A small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors.

BioNTech, the German developer of a widely used mRNA vaccine for the coronavirus, agreed to pay US$800 million (HK$6.24 ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

BioNTech, the German pharmaceutical company, announced on Wednesday that it has reached an agreement to acquire Biotheus, a Chinese biotechnology fir ...

BioNTech’s goal is to improve its research and treatments via Biotheus’ offering, combining their attempts to conquer cancer. The acquisition is going to expand the German drugmaker’s reach in China ...

The acquisition is centered around Biotheus’ main asset, BNT327/PM8002, which works by boosting the immune system to attack ...

The hope is that patients who are given the personalised vaccines have a better chance of long-term survival and cure' ...

BioNTech SE (BNTX) has released an update. BioNTech SE is set to acquire Biotheus in a deal valued at $800 million, aiming to strengthen its ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...

BioNTech said the combination aimed to enable the immune system to recognise and attack cancer cells, while simultaneously ...